Australian Institute of Health and Welfare 2019. Gout . Cat. no. PHE259. Canberra: AIHW. Viewed 13 November 2019, https://www.aihw.gov.au/reports/chronic-musculoskeletal-conditions/gout
Australian Institute of Health and Welfare. (2019). Gout . Retrieved from https://www.aihw.gov.au/reports/chronic-musculoskeletal-conditions/gout
Gout . Australian Institute of Health and Welfare, 30 August 2019, https://www.aihw.gov.au/reports/chronic-musculoskeletal-conditions/gout
Australian Institute of Health and Welfare. Gout [Internet]. Canberra: Australian Institute of Health and Welfare, 2019 [cited 2019 Nov. 13]. Available from: https://www.aihw.gov.au/reports/chronic-musculoskeletal-conditions/gout
Australian Institute of Health and Welfare (AIHW) 2019, Gout , viewed 13 November 2019, https://www.aihw.gov.au/reports/chronic-musculoskeletal-conditions/gout
Get citations as an Endnote file:
Gout is a form of inflammatory arthritis that develops when an excess of uric acid in the blood leads to deposits of uric acid crystals in one or more joints, causing inflammation.
0.8% of Australians had gout in 2017–18, based on self-reported survey data. That is approximately 187,000 people
Men are more likely to have gout than women—almost 9 in 10 (87%) people with gout are men
Gout can be managed or even prevented by long-term therapy with medications and life style changes to control hyperuricaemia and reduce levels of uric acid in the body.
Gout can be controlled with early and ongoing treatment, including:
Flares and complications can be managed by reducing risk factors for hyperuricaemia (dehydration, obesity and alcohol intake), taking urate-lowering medications to keep uric acid levels low, and managing comorbid conditions, such as high blood pressure, chronic kidney disease, diabetes and heart disease.
The use of non-steroidal anti-inflammatory drugs (NSAIDs), low-dose colchicine and oral/intra-muscular/intra-articular glucocorticoids has also been found to be effective in managing acute gout. It has been recommended that people with gout should continue urate-lowering therapy for the rest of their lives .
Data from the AIHW National Hospital Morbidity Database (NHMD) show that, in 2016-17:
Source: AIHW National Hospital Morbidity Database (Data table).
The age-standardised hospitalisation rate for Australians with gout increased between 2005–06 and 2016–17: from 20 hospitalisations per 100,000 population to 28 per 100,000 population. There was a slightly larger increase for females (57%, from 7 to 11 per 100,000 population) compared with males (40%, from 34 to 47 per 100,000 population).
We'd love to know any feedback that you have about the AIHW website, its contents or reports.